Neuraltus Pharmaceuticals, Inc. is a privately-held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet needs, primarily in the treatment of neurodegenerative diseases. Neuraltus’s lead product, NP001, is in clinical development for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.

Patents show all

35Applications17Issued

Clinical Trials show all

2Phase 12Phase 21Phase 1/Phase 2

SEC Filings show all

D3

Overview

Total FundingEmployeesLast Funding DateStatus
$54,165,0061-102016-05-24Operating

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2012-01-31$9,600,000VentureVantagePoint Capital Partners, Latterell Venture Partners, Adams Street Partners
2016-05-24$14,938,357VentureVantagePoint Capital Partners, Latterell Venture Partners
2012-04-01$1,501,000VentureAdams Street Partners, Latterell Venture Partners
2012-05-30$11,125,649Venture
2009-03-26$17,000,000VentureVantagePoint Capital Partners, Adams Street Partners, Latterell Venture Partners

SEC Form D Funding Events

DateOfferedSoldType
2012-05-31$11,125,649$11,125,649Equity, Option to Acquire, Other
2009-04-07$18,000,000$4,893,853Equity, Security to be Acquired, Other

Key Executives

  • Ari Azhir
    Executive Officer, Director
  • James N. Woody
    Director
  • Annette Bianchi
    Director
  • Terry Gould
    Director
  • Andrew Gengos
    Executive Officer, Director
  • James Woody
    Director
  • John Walker
    Director